WCM
VIRX

Whitener Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Whitener Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-48
Closed -$1K – 457
2019
Q3 		$1K Hold
48
– – ﹤0.01% 475
2019
Q2 		$1K Hold
48
– – ﹤0.01% 465
2019
Q1 		$2K Hold
48
– – ﹤0.01% 443
2018
Q4 		$0 Hold
48
– – ﹤0.01% 478
2018
Q3 		$3K Buy
+48
New +$3.65K ﹤0.01% 414
2018
Q2 		– Sell
-48
Closed -$4K – 435
2018
Q1 		$4K Hold
48
– – ﹤0.01% 399
2017
Q4 		$6K Buy
+48
New +$4.5K 0.01% 361

Other funds holding VIRX

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Whitener Capital Management's VIRX Position: Q4 2019 in Review

Whitener Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2019, closing a stake of 48 shares — an estimated $1K sold.

Whitener Capital Management first reported a position in VIRX in Q4 2017 and held it in 7 quarters. The position peaked at $6K in Q4 2017. 44 funds tracked by Wall St. Rank hold VIRX as of Q4 2019.

  • Whitener Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Whitener Capital Management sold 48 Viracta Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1K.
  • Whitener Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
  • Whitener Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $6K in Q4 2017.
  • 44 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Whitener Capital Management's 13F filing for Q4 2019, filed 12 Feb 2020.